Hualan Biological Engineering 

¥16.25
0
+¥0.54+3.44% 今天

統計

當日最高
16.47
當日最低
15.65
52週最高
24.55
52週最低
13.72
成交量
19,163,186
平均成交量
11,025,242
市值
39.99B
市盈率
37.15
股息收益率
1.89%
股息
0.31

即將到來

股息

1.89%股息收益率
10年增長
-0.25%
5年增長率
N/A
3年增長率
N/A
1年增長率
N/A

收益

28Oct預期
Q1 2024
Q2 2024
下一個
0.1
0.17
0.24
0.31
預期每股收益
0.31489567262999996
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 002007.SZ 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.
Show more...
首席執行官
Mr. Kang An
員工
3243
國家
CN
ISIN
CNE000001JN8

上市公司